Adjuvants for vaccines against respiratory syncytial virus
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Mar 3, 1998
Grant Date -
N/A
app pub date -
Sep 16, 1996
filing date -
May 25, 1993
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Vaccine formulations and therapeutic methods therefor containing respiratory syncytial viral proteins or immunological fragment and an adjuvant selected from the group consisting of QS-21 3-deacylated monophosphoryl lipid A, monopohosphoryl lipid A and combination are described herein. Presence of the adjuvant(s) significantly increases the humoral and cell-mediated immunogenicity of the RSV proteins.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully